Compare Biogen Inc (BIIB) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs JPMorgan Chase & Co — how do they compare? Biogen Inc trades at $206.52 (market cap $30.13B), while JPMorgan Chase & Co trades at $365.01 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 31.9× Biogen Inc's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | JPM | |
|---|---|---|
Market Cap | $30.13B | $962.37B |
Sector | Health | Financials |
52-Week High | $216.63 | $362.04 |
52-Week Low | $128.93 | $282.84 |
Enterprise Value | $37.20B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
JPMorgan Chase & Co. (JPM) trades at $365.11, up 1.48% in 24 hours, with a bullish technical signal and strong fundamentals including a 33.38% net income margin and 18.43% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Moderate Buy with a $374.18 price target. CEO Jamie Dimon's shareholder letter highlights economic risks, but institutional buying and resilient sector performance support optimism.
The outlook for JPM is positive, driven by earnings momentum and sector strength, though risks include geopolitical tensions and potential economic headwinds noted by management. Upside to the consensus target offers opportunity, but investors should weigh high RSI levels and macroeconomic cautions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
